METHYLGENE
MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which ha... s completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.
METHYLGENE
Industry:
Biopharma Biotechnology Clinical Trials
Founded:
1997-01-01
Address:
Montréal, Quebec, Canada
Country:
Canada
Website Url:
http://www.methylgene.com
Total Employee:
11+
Status:
Closed
Contact:
514.337.3333
Email Addresses:
[email protected]
Total Funding:
71.83 M USD
Technology used in webpage:
SPF Amazon Amazon Frankfurt Region Lighttpd
Current Advisors List
Current Employees Featured
Founder
Investors List
Tavistock Life Sciences
Tavistock Life Sciences investment in Venture Round - MethylGene
Baker Brothers Advisors LLC
Baker Brothers Advisors LLC investment in Venture Round - MethylGene
Tang Capital Management
Tang Capital Management investment in Venture Round - MethylGene
OrbiMed
OrbiMed investment in Venture Round - MethylGene
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Venture Round - MethylGene
ProQuest Investments
ProQuest Investments investment in Venture Round - MethylGene
RBC Capital
RBC Capital investment in Venture Round - MethylGene
Canadian Medical Discoveries Fund
Canadian Medical Discoveries Fund investment in Venture Round - MethylGene
Sofinov Societe Financiere D'Innovation
Sofinov Societe Financiere D'Innovation investment in Venture Round - MethylGene
Societe Innovatech du Grand Montreal
Societe Innovatech du Grand Montreal investment in Venture Round - MethylGene
Official Site Inspections
http://www.methylgene.com
- Host name: 104.21.91.54
- IP address: 104.21.91.54
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "MethylGene"
MethylGene - Crunchbase Company Profile & Funding
MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on …See details»
Organization | MethylGene Inc.
MethylGene Inc. Report issue. For profit Phase 1 Phase 2. Founded: Montreal Canada ... Organization Overview. First Clinical Trial. 2004 NCT00323934. First Marketed Drug. None …See details»
MethylGene Inc. - LinkedIn
MethylGene Inc. (TSX: MYG) is a clinical-stage biopharmaceutical company that develops novel therapeutics for cancer and infectious disease.See details»
MethylGene Inc. | BDC.ca
MethylGene is a biopharmaceutical company focused on the discovery, development and commercialization of novel and proprietary enzyme inhibitors for the treatment of cancer and infectious diseases.See details»
MethylGene Inc Company Profile | Saint-Laurent, QC, Canada ...
Find company research, competitor information, contact details & financial data for MethylGene Inc of Saint-Laurent, QC. Get the latest business insights from Dun & Bradstreet.See details»
MethylGene Inc. - VentureRadar
MethylGene (TSX: MYG) is a clinical-stage biopharmaceutical company that develops novel therapeutics for cancer and infectious disease. The Company is focused on its two lead …See details»
Methylgene - Products, Competitors, Financials, Employees, …
About MethylGene MethylGene is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer and infectious …See details»
Mirati Therapeutics - Pappas Capital
Mirati Therapeutics (formerly MethylGene) is a targeted oncology company developing a pipeline of oncology therapeutics for precisely defined patient populations. Mirati is currently advancing …See details»
MethylGene - Contacts, Employees, Board Members, Advisors
MethylGene is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer therapeutics.See details»
MethylGene - Funding, Financials, Valuation & Investors
MethylGene is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer therapeutics.See details»
MethylGene Announces Plan to Reincorporate in the United States …
May 9, 2013 · MethylGene Inc. today announced that its Board of Directors , after careful analysis, consideration and advice from its legal, tax and accounting advisors, has …See details»
MethylGene Shareholders Approve the Plan of Arrangement to ...
Jun 25, 2013 · MethylGene Inc. today announced that at its Annual and Special Meeting of Shareholders held in Montreal, Quebec , that over 99.99% of the votes cast by shareholders …See details»
| BioWorld
Jun 27, 2003 · MethylGene Inc. could earn $33.75 million in a deal with Merck-Frosst Canada & Co. to develop a small-molecule inhibitor program against bacterial beta-lactamases to fight …See details»
METHYLGENE REACQUIRES RIGHTS TO MGCD0103 FROM …
October 27, 2008 - MethylGene Inc. (TSX:MYG) today announced that Celgene has terminated their licensing agreement for oncology histone deacetylase (HDAC) inhibitors, including …See details»
Cancer drug developer MethylGene raises $34.5M
Mar 25, 2011 · Canada's MethylGene is raising $34.5 million through the private placement of shares and warrants to fund mid-stage trials of two oncology drugs.See details»
DNA Methylation: What Is Its Role in Carcinogenesis?
May 17, 2000 · Methylgene Inc., a Montreal-based company, entered MG98—an antisense drug targeting DNA methyltransferase —in phase I clinical trials last year. The National Cancer …See details»
Breaking the Silence: The Rise of Epigenetic Therapy
Jun 19, 2002 · MethylGene, a Montreal biotech company, is preparing its own HDAC inhibitors for the clinic, and is also analyzing the separate roles of the 11 known HDACs in cancer. That’s …See details»
Preclinical development of MGCD265, a potent orally active c …
May 1, 2008 · MethylGene has developed a small molecule inhibitor, MGCD265 that potently inhibits c- Met, Ron, all three members of the VEGFR family and Tie-2, thereby inhibiting …See details»
MethylGene Reports Results of Phase II Trial of MGCD290
MethylGene Inc. (TSX:MYG) today reported topline results from its human efficacy trial (Trial 290-005) with MGCD290, a novel antifungal agent targeting the fungal enzyme, Hos2.See details»
MethylGene Inc. Reports Results of Phase II Trial of MGCD290
Mar 18, 2013 · MethylGene Inc. reported results from its human efficacy trial with MGCD290, a novel antifungal agent targeting the fungal enzyme, Hos2. Trial 290-005 was a randomized, …See details»